BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The primarily objective of this study is to assess the effect of switching from Tenofovir Disoproxil Fumurate (TDF) to TAF based ART on bone mass and turnover among women on DMPA for contraception. HIV virologically suppressed women on DMPA will be switched from their TDF based regimen to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®) in a randomized fashion. HIV infected women on TDF and non‐hormonal contraception will be switched to Biktarvy®).
Epistemonikos ID: 8d4d0913f240b97cf4b25d2eaac28d9fc606953d
First added on: May 22, 2024